Driven by innovation and purposeful science
Sumitomo Pharma Oncology, Inc. is a developer of novel cancer therapeutics based in the U.S. and a wholly owned subsidiary of Sumitomo Pharma Co., Ltd. This U.S. entity, together with the oncology research and development teams in Japan, Cancer Research Unit, and Oncology Clinical Development Unit, will collectively be known as Sumitomo Pharma Oncology or SMP Oncology.
SMP Oncology brings together a team of highly engaged oncology experts who leverage their passion for challenging work to collaborate across geographies and realize a common goal—advancing purposeful science by transforming new discoveries into meaningful therapeutic options for patients with cancer.
At SMP Oncology, we are relentlessly exploring novel and unique approaches to address unmet needs in oncology research and development. Through scientific persistence and a commitment to discovery, we are focused on advancing a diverse and purposeful pipeline.
Learn more about our leadership.
SMP Oncology is committed to developing a diverse and purposeful pipeline of novel targets.
We also have a responsibility to serve our local communities. From Utah to Massachusetts to Japan, we are committed to supporting and understanding the needs of patients and families living with cancer.
Learn more about our community efforts.